at CNBC.com (Sep 25, 2014)
LipoScience (LPDX +0.6%) moves up after Piper Jaffray initiates the shares with an Overweight and a $15.00 price target. Piper notes that ongoing traction converting its LDL-C patient monitoring assays to LDL-P and represents a potential $330M annual revenue run-rate, which would exceed both its top and bottom-line projections. Separately, Barclay's and UBS also initiated coverage with an Overweight and Buy, respectively.
From other sites